(Q33504469)

English

Modified ice study: a phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Modified ice study: a phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shevlin PM

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Muers MF

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Peake MD

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Hosker HS

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Stead ML

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Poulter KM

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Brown JM

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

publication date

1 August 1998

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

115-126

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Carcinoma of the bronchus in the Yorkshire region of England 1976-1990: trends since 1984.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Canc

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Part

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychosocial well-being of patients with inoperable non-small cell lung cancer. The importance of treatment- and disease-related factors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? West of Scotland Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900035-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(98)00035-X

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33504469&oldid=1582959154"